Bo Yan1, Wei Zhang1, Li-Yan Jiang1, Wen-Xin Qin2, Xin Wang3. 1. Department of Respiratory, Shanghai Chest Hospital, Shanghai Jiao Tong University Shanghai 200030, P.R. China. 2. Shanghai Cancer Institute Shanghai 200032, P.R. China. 3. Department of Respiration, General Hospital of Jinan Military Command No. 25 Shifan Road, Jinan 250031, P.R. China.
Abstract
OBJECTIVE: Previous studies related to the prognostic value of E-Cadherin expression on non-small cell lung cancer (NSCLC) were inconsistent. The present study aimed to evaluate the relation between E-Cadherin expression and the prognosis of NSCLC. METHODS: We performed a meta-analysis based on 14 studies including 2395 NSCLC patients. Literature retrieval, data extraction, and meta-analyses were performed according to the Revman 5.0 guidelines. We utilized the fixed-effect model to pool the HR according to the test of heterogeneity in the meta-analysis. RESULTS: A total of 14 eligible studies including 2395 NSCLC patients were analyzed. In total, 51.2% of the patients were considered as having reduced expression of E-Cadherin according to the authors' cutoff. The pooled hazard ratio (HR) of reduced expression of E-Cadherin for overall survival (OS) was 1.19 (95% CI: 1.01 to 1.40, P=0.04), showing a worse survival when E-Cadherin expression is decreased. CONCLUSION: Patients with reduced expression of E-cadherin have a poorer OS compared with those with normal or high expression of E-cadherin.
OBJECTIVE: Previous studies related to the prognostic value of E-Cadherin expression on non-small cell lung cancer (NSCLC) were inconsistent. The present study aimed to evaluate the relation between E-Cadherin expression and the prognosis of NSCLC. METHODS: We performed a meta-analysis based on 14 studies including 2395 NSCLCpatients. Literature retrieval, data extraction, and meta-analyses were performed according to the Revman 5.0 guidelines. We utilized the fixed-effect model to pool the HR according to the test of heterogeneity in the meta-analysis. RESULTS: A total of 14 eligible studies including 2395 NSCLCpatients were analyzed. In total, 51.2% of the patients were considered as having reduced expression of E-Cadherin according to the authors' cutoff. The pooled hazard ratio (HR) of reduced expression of E-Cadherin for overall survival (OS) was 1.19 (95% CI: 1.01 to 1.40, P=0.04), showing a worse survival when E-Cadherin expression is decreased. CONCLUSION:Patients with reduced expression of E-cadherin have a poorer OS compared with those with normal or high expression of E-cadherin.